We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesMolecular Templates Inc

Molecular Templates Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-05-21T13:44:02.228062Z
Market Cap
8.23M

Momentum Score

…

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.16
Low
9.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
31.76M
Revenue Per Share
6.47
Gross Profit TTM
-45.97M
Debt / Equity
2.90
ROE
-929.14%
Net Debt
0.71M
ROCE
-492.03%
Diluted EPS TTM
-4.61

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -92.67M -83.01M 104.91M -69.42M -30.29M
Net income -92.72M -79.31M 104.92M -69.54M -30.29M
Selling general administrative 26.20M 34.11M 26.72M 20.08M 14.08M
Gross profit 19.75M 38.70M 18.84M 19.50M 13.29M
Reconciled depreciation 7.38M 6.63M 3.92M 1.18M 0.97M
Ebit -88.87M -86.70M 106.63M -70.45M -31.22M
Ebitda -87.88M -80.07M 110.54M -46.00M -30.25M
Depreciation and amortization 0.99M 6.63M 3.92M 24.45M 0.97M
Non operating income net other - - -3.39M 0.00M 0.95M
Operating income -88.87M -80.07M -100.84M -70.45M -31.00M
Other operating expenses 108.62M 118.77M 119.69M 67.83M 38.28M
Interest expense 4.78M 3.37M 1.71M 1.30M 0.99M
Tax provision 0.05M 0.00M 0.01M - -
Interest income 0.99M 0.43M 1.03M 2.32M 0.75M
Net interest income -3.79M -2.94M -0.68M 1.02M -0.24M
Income tax expense 0.05M -3.69M 0.01M 0.12M 1.70M
Total revenue 19.75M 38.70M 18.84M 19.50M 7.28M
Total operating expenses 108.62M 118.77M 119.69M 67.83M 38.28M
Cost of revenue - - - 50.52M -6.00M
Total other income expense net -3.79M -2.94M 205.75M 1.03M 0.95M
Net income from continuing ops -92.72M -83.01M -104.92M -69.42M -30.29M
Net income applicable to common shares -92.72M -83.01M -104.92M -69.42M -30.29M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 35.38M 97.55M 192.36M 139.88M 174.20M
Intangible assets - - - - 1.20M
Other current assets 5.00M 3.79M 1.25M 1.12M 0.49M
Total liab 31.17M 112.68M 126.70M 80.54M 71.17M
Total stockholder equity 4.21M -15.13M 65.66M 59.34M 103.03M
Deferred long term liab - - 33.35M 4.54M 19.39M
Other current liab 4.28M 8.82M 9.52M 18.19M 2.50M
Common stock 0.01M 0.06M 0.06M 0.05M 0.05M
Capital stock 0.01M 0.06M 0.06M 0.05M 0.05M
Retained earnings -452.89M -444.77M -352.05M -269.04M -164.12M
Other liab - 7.20M 34.98M 15.85M 20.75M
Other assets 0.00M 3.49M 7.24M 5.20M 3.48M
Cash 11.52M 32.19M 24.98M 25.22M 85.45M
Total current liabilities 17.32M 57.08M 46.67M 37.55M 35.80M
Current deferred revenue 9.03M 45.57M 32.94M 14.80M 17.29M
Net debt 0.71M 18.39M 20.07M 1.92M -70.83M
Short term debt 2.49M 2.18M 2.61M 2.21M 14.54M
Short long term debt total 12.23M 50.58M 45.05M 27.14M 14.62M
Other stockholder equity 457.10M 429.65M 417.70M 328.31M 267.09M
Property plant equipment - 25.76M 19.31M 33.36M 18.16M
Total current assets 16.77M 68.30M 148.22M 101.32M 139.90M
Long term investments - 0.00M 8.99M 0.00M 1.51M
Net tangible assets - -15.13M 65.66M 59.34M 103.03M
Short term investments 0.00M 28.86M 118.06M 68.67M 39.63M
Net receivables 0.25M - 0.00M 0.23M 7.51M
Long term debt - 36.17M 35.49M 14.93M 2.94M
Inventory - - - 6.08M 6.82M
Accounts payable 1.52M 0.50M 1.61M 2.35M 1.47M
Accumulated other comprehensive income - -0.07M -0.05M 0.02M 0.02M
Common stock total equity - - 0.06M 0.05M 0.05M
Retained earnings total equity - - -352.05M -269.04M -164.12M
Non currrent assets other 0.74M 3.49M 7.24M 5.20M 4.68M
Non current assets total 18.61M 29.25M 44.15M 38.55M 34.30M
Capital lease obligations 12.23M 14.41M 9.56M 14.42M 11.68M
Long term debt total - - 35.49M 14.93M 2.94M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 95.32M -58.44M -34.66M -30.07M -10.22M
Change to liabilities -15.92M -4.50M -13.73M 7.15M 1.16M
Total cashflows from investing activities 95.32M -62.44M -34.66M -39.72M -15.95M
Net borrowings - 19.83M 9.48M 0.03M 0.89M
Total cash from financing activities -0.27M 92.59M 58.90M 65.70M 49.22M
Change to operating activities -1.40M -15.42M 7.75M 8.95M 1.62M
Net income -92.72M -83.01M -104.92M -69.42M -30.29M
Change in cash 6.03M -0.23M -59.56M 0.73M 28.81M
Begin period cash flow 28.65M 28.89M 88.45M 87.72M 58.91M
End period cash flow 34.68M 28.65M 28.89M 88.45M 87.72M
Total cash from operating activities -89.02M -30.39M -83.80M -25.24M -4.46M
Issuance of capital stock 0.00M 71.14M 48.37M 63.92M 48.05M
Depreciation 7.38M 6.63M 3.92M 1.18M 0.97M
Other cashflows from investing activities - - 0.01M -30.07M -10.22M
Change to inventory - -15.66M 14.94M 3.37M -2.29M
Change to account receivables 0.00M 0.23M 0.17M -0.17M -0.24M
Sale purchase of stock - 72.77M 49.41M 65.67M 48.34M
Other cashflows from financing activities -0.27M 21.45M 15.72M 1.81M 4.82M
Change to netincome 12.53M 17.07M 15.33M 28.00M 3.07M
Capital expenditures 3.20M 4.00M 7.39M 9.65M 5.72M
Change receivables - 0.23M 0.17M -0.17M -0.24M
Cash flows other operating - 32.31M 5.57M 7.46M 20.51M
Cash and cash equivalents changes - -0.23M -59.56M 0.73M 28.81M
Change in working capital -17.31M 27.90M 1.30M 14.44M 21.43M
Stock based compensation 11.91M 16.63M 11.82M 5.86M 3.99M
Other non cash items 1.72M 1.02M 0.68M 0.56M 0.23M
Free cash flow -92.22M -34.38M -91.19M -34.89M -10.19M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

9301 Amberglen Boulevard, Austin, TX, United States, 78729

512 869 1555

https://www.mtem.com

62

Name Title Year Born
Dr. Eric E. Poma Ph.D. CEO, Chief Scientific Officer & Director 1972
Ms. Jason S Kim Pres & COO 1975
Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer 1968
Mr. Sean McLennan Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer 1970
Ms. Megan C. Filoon Gen. Counsel & Sec. NA
Mr. Kurt Elster Exec. VP of Corp. Devel. 1967
Dr. Jack Higgins Ph.D. Exec. VP of Operations & Head of Manufacturing 1980
Dr. Erin Willert Ph.D. Exec. VP of R&D 1982
Dr. Jen-Sing Liu Ph.D. Exec. VP of Manufacturing 1963
Mr. Michael Dowd Sr. VP of Project & Alliance Management NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…